SCHEMBL1418969

SCHEMBL1418969

O=Cc1cccn1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.65
ATM Q13315 2/20 0.57
LMNA P02545 3/20 0.56
MAPT P10636 2/20 0.56
NPC1 O15118 1/20 0.56
RAB9A P51151 1/20 0.56
NPSR1 Q6W5P4 1/20 0.56
L3MBTL1 Q9Y468 2/20 0.49
CYP1A2 P05177 1/20 0.49
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
POLB P06746 2/20 0.41
GAA P10253 2/20 0.41
TRIM24 O15164 1/20 0.41
TRIM33 Q9UPN9 1/20 0.41
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14908383 0.81 MAPT (0.47) ALDH1A1ATMLMNAMAPTNPC1
SCHEMBL4001880 0.80 ATM (0.65) ALDH1A1ATMLMNAMAPTNPC1
SCHEMBL27951608 0.77 MAPT (0.44) ALDH1A1LMNAMAPTNPC1RAB9A
SCHEMBL6052462 0.76 ATM (0.69) ALDH1A1ATMLMNAL3MBTL1CYP1A2
SCHEMBL28469213 0.76 EPHX2 (0.48) ALDH1A1MAPTPPARA
SCHEMBL10059454 0.76 MAPT (0.50) ATMLMNAMAPTNPC1RAB9A
SCHEMBL25283656 0.75 PIM1 (0.65) LMNAMAPTNPC1RAB9ANPSR1
SCHEMBL25251851 0.75 PIM1 (0.65) LMNAMAPTNPC1RAB9ANPSR1
SCHEMBL1127259 0.74 ATM (1.00) ALDH1A1ATMLMNAMAPTL3MBTL1
SCHEMBL3969097 0.74 NOD1 (0.43) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME MEDIFIC, INC. (KR) 2025-02-27 US disclosed
EP-4455143-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME Medific, Inc. (KR) 2024-10-30 EP disclosed
CN-118591539-A Substituted thiazolidinedione derivative compounds and pharmaceutical composition for preventing or treating cancer comprising the same (株)美迪菲 2024-09-03 CN disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 WO disclosed
WO-2023121184-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME (주)메디픽 2023-06-29 WO disclosed
US-7994199-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2011-08-09 US disclosed
EP-2305664-A1 Anabaseine derivatives useful in the treatment of neurodegeneratives diseases Memory Pharmaceuticals Corporation (US) 2011-04-06 EP disclosed
EP-2298758-A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases Memory Pharmaceuticals Corporation (US) 2011-03-23 EP disclosed
EP-2298759-A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases Memory Pharmaceuticals Corporation (US) 2011-03-23 EP disclosed
US-20100173891-A1 HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF HERBERT BRIAN 2010-07-08 US disclosed
US-7700630-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORPORATION (US) 2010-04-20 US disclosed
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system HERBERT BRIAN 2009-04-23 US disclosed
US-7244745-B2 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. (US) 2007-07-17 US disclosed
EP-1531820-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES Memory Pharmaceuticals Corporation (US) 2005-05-25 EP disclosed
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof MEMORY PHARMACEUTICALS CORP. 2004-11-18 US disclosed
WO-2004019943-A1 ANABASEINE DERIVATIVES USEFUL IN THE TREATMENT OF NEURODEGENERATIVE DISEASES MEMORY PHARMACEUTICALS CORPORATION (US) 2004-03-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040229868-A1 Heterocyclic compounds, methods for the preparation thereof, and uses thereof CHRNA1, CHRNA4, CHRNA3 ALDH1A1 370/4885ATM 4792/4885LMNA 2297/4885
US-20090105215-A1 3-Quinolin-2-ylmethylene-3,4,5,6-terahydro[2,3']bipyridinyl; for therapy and prophylaxis of psychotic diseases, neurodegenerative diseases involving a dysfunction of the cholinergic system CHRNA3, CHRNA2, CHRNA5 ALDH1A1 1867/4885ATM 4218/4885LMNA 2965/4885
US-20100173891-A1 HETEROCYCLIC COMPOUNDS, METHODS FOR THE PREPARATION THEREOF, AND USES THEREOF CHRM3, CHRNA1, CHRNA5 ALDH1A1 656/4885ATM 4586/4885LMNA 2358/4885
US-20250066347-A1 SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVE COMPOUND, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER, COMPRISING SAME SREBF1, SREBF2, SP1 ALDH1A1 1168/4885ATM 914/4885LMNA 2364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.